Jaxteran (Dimethyl Fumarate)

Dimethyl fumarate activates the Nrf2 cellular pathway, which boosts antioxidant defenses and modulates immune cell function. By shifting the balance toward anti‑inflammatory responses, it reduces the production of pro‑inflammatory cytokines and limits tissue damage in the central nervous system and skin.

The dosage of Jaxteran is individualized by the prescribing clinician based on the patient’s condition, disease severity, and tolerability. The prescriber determines the appropriate starting dose and any subsequent titration, following approved labeling and clinical guidelines.

Safety of dimethyl fumarate in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and the drug should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women should discuss alternatives with their healthcare provider.

To request Jaxteran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Jaxteran (dimethyl fumarate) is an oral immunomodulator, offering a convenient administration route compared with injectable or infusion therapies. Its efficacy in reducing relapse rates is comparable to several first‑line agents, while its safety profile includes a higher incidence of flushing and lymphopenia but a lower risk of injection‑site reactions.

Store Jaxteran at ambient temperature, preferably below 25 °C, in the original container to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid environments such as bathrooms.

Jaxteran is taken orally, usually with food to lessen gastrointestinal discomfort. The tablets are swallowed whole with a full glass of water and should not be crushed, chewed, or split unless specifically instructed by a healthcare professional.

The most serious risks include progressive multifocal leukoencephalopathy (PML), severe liver injury, and anaphylactic reactions. Patients should be monitored regularly for signs of infection, liver enzyme elevations, and any allergic symptoms, and they should report new neurological or systemic signs promptly.

Jaxteran is contraindicated in patients with known hypersensitivity to dimethyl fumarate or any excipients, those with active serious infections, and individuals receiving live attenuated vaccines. Caution is also advised for patients with severe lymphopenia, significant liver disease, or those who are pregnant or breastfeeding without a clear benefit.